Get the content you want anytime you want.
REGISTER NOW | SIGN IN
ARTICLE

First Therapeutic Vaccine for Genital Herpes Reduces Signs of Infection for One Year

JUN 22, 2016 | SARAH ANWAR
A therapeutic vaccine for genital herpes has the potential to reduce viral activity as well as decrease the number of days of recurrent herpes, as observed in a phase II clinical trial.
 
In a press conference on June 19, 2016, Kenneth Fife, MD, PhD, professor of medicine in the Department of Medicine, Department of Microbiology, and Department of Pathology at Indiana University, School of Medicine, announced that GEN-003, a three-injection immunotherapy, recruits T-cells to control the virus, as well as stimulates antibodies to neutralize herpes for up to one year.
 
Speaking with Contagion, Dr. Fife discussed current antiviral treatments in comparison to the novel therapy developed by his team.
 


FEATURED
Big advances in treatment can